Botanix Pharmaceuticals (BXPHF) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, and welcome to the PLUS 500 H1 2025 interim results. The presentation will commence shortly. After the presentation, we will conduct a Q&A session. If you wish to ask a question, you'll be able to ask a question either through the Zoom webinar link provided separately or by submitting written questions using the ask a question button on the Spark Live webcast page. Please note this call is being live streamed to a webcast for a wider audience and will be recorded. I would now like to hand over to David Shreer, Group Chief Executive Officer, to open the presentation. Please go ahead. Good morning, everyone, and thank you for joining our 2025 Interim Results Presentation. I am David Zrouya, CEO of Plus500, and I am joined today by Elad Evenhen, our Group CFO, and Owen Jones, our Group Head of Investor Relations. During the first six months of 2025, Plus500 is globally diversified. Multi-asset offering drove an acceleration of positive momentum across a number of important strategic initiatives, which we will highlight to you today. Our differentiated offerings, which are powered by our proprietary technology provides us with strong competitive advantages, and we remain committed to delivering seamless and innovative access to financial markets worldwide. The structural growth opportunities ahead of us are compelling, and we look to the year ahead and beyond with confidence. As always, I would like to thank all of the people of Philosophy Fund-RED who once again made these results possible for their hard work and continued dedication towards successfully achieving our collective goals and strategic ambitions. Slide two shows the agenda for today. We will take you to the highlights for the first half and the operating review, followed by a run throu...